EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lupin's Enterprise Value is ₹771,530 Mil.
Lupin's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹27,339 Mil. Therefore, Lupin's EV-to-EBIT for today is 28.22.
The historical rank and industry rank for Lupin's EV-to-EBIT or its related term are showing as below:
BOM:500257'
s EV-to-EBIT Range Over the Past 10 Years
Min: -144.22 Med: 23.15 Max: 160.51
Current: 28.22
During the past 13 years, the highest EV-to-EBIT of Lupin was 160.51. The lowest was -144.22. And the median was 23.15.
BOM:500257's EV-to-EBIT is ranked worse than 69.76% of 668
companies
in the Drug Manufacturers industry
Industry Median: 17.92
vs BOM:500257: 28.22
The historical data trend for Lupin's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lupin's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lupin's EV-to-EBIT Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lupin's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lupin's EV-to-EBIT falls into.
Lupin's current Enterprise Value is ₹771,530 Mil.
Lupin's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹27,339 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lupin (BOM:500257) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lupin's Enterprise Value for the quarter that ended in Mar. 2024 was ₹740,390 Mil.
Lupin's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹27,339 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lupin EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Lupin's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Lupin Ltd is a specialty and generic drug manufacturing company. The company's global formulations business develops and delivers a wide range of branded and generic formulations across the globe. The operations of the company are limited to one segment, namely pharmaceuticals and related products. The company also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:500257 has been successfully added to your 